Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.
Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...
Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...
Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly ...
Glenmark launches Empagliflozin and combinations in India under Glempa brand, aiming to improve glycemic control and reduce ...
According to the company's statement, these medications are designed to improve glycemic control in adults with Type 2 Diabetes while also reducing cardiovascular outcomes in the patients.
Glenmark Pharmaceuticals launches Empagliflozin, an SGLT2 inhibitor, in India under the brand name Glempa for glycemic ...
Glenmark Pharmaceuticals announced that it has launched generic Empagliflozin, a widely recognized SGLT2 inhibitor, in India.
MT Newswires on MSN2d
Indian Markets End Lower on Wednesday as IT Stocks WeighIndian equity benchmarks ended slightly lower on Wednesday as a decline in information technology stocks on US growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback